[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pollution-related-respiratory-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pollution-related-respiratory-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642947","lung-and-heart-function-across-decades-of-life-in-health-100642947",false,"NCT07641413","Lung and Heart Function Across Decades of Life in Health","Lung and Heart Function Across Decades of Life in Healthy Population","Inclusion Criteria:\n\n* Age 24-68\n* No respiratory complaints (defined as modified Medical Research Council score = 0)\n* No use of respiratory medications\n\nExclusion Criteria:\n\n* Non-English speaking\n* Pregnancy\n* BMI\\>35 Kg\u002Fm2\n* Tobacco smoking within prior year\n* Lifetime tobacco smoking of \\>5 pack-years\n* Current inhaled cannabis use (any modality) \\>2x weekly\n* Prior inhaled cannabis uses exceeding 2x weekly within the prior year\n* Illicit drug use (other than cannabis)\n* No prior or current major organ disease, including but not limited to:\n\n  * Neuromuscular weakness\n  * History of malignancy (other than non-melanoma skin cancer)-- HIV\u002FAIDS\n  * Autoimmune disease\n  * Solid-organ or hematopoietic stem cell transplant\n  * Cardiovascular disease (other than mild HTN; \\\u003C 140\u002F90; controlled on 2 or less medications)\n\n    * Poorly-controlled HTN (SBP\\>140 or DBP\\>90 or use of more than 2 anti-hypertensive medications)\n    * Any history of congestive heart failure (CHF, either HFpEF or HFrEF)\n    * Any history of arrythmia (including atrial fibrillation)",true,"ALL","24 Years","68 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The main objective of this study is to develop baseline \"normal\" reference values of both lung and heart function for healthy adults within the age range relevant to the United States Veteran population who served in the Southwest Asia theater of military operations.\n\nThis study will involve performing key components of the Department of Veterans Affairs the Airborne Hazards and Open Burn Pit Center of Excellence (AHOBPCE) and a VA network of Post-Deployment Cardiopulmonary Evaluation Network (PDCEN) Core Clinical Evaluation in asymptomatic unexposed healthy controls without known lung or heart disease to serve as a \"normal\" control comparator group for veterans evaluated by PDCEN.",[26,27,28,29],"Pollution Related Respiratory Disorder","Pollution; Exposure","Dyspnea","Cardiopulmonary",[31,32,33,34,35,36],"Cardiopulmonary function","Pulmonary function testing","Forced oscillometry testing","Echocardiography","Cardiopulmonary exercise testing","Computed tomography imaging","RECRUITING","2026-06-08",{"date":40,"type":41},"2026-06-11","ACTUAL",{"date":43,"type":41},"2024-08-01",{"date":45,"type":22},"2030-12-31",{"name":47,"class":48},"University of California, San Francisco","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":80,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100556807","environmental-exposure-to-heavy-metals-nanoparticles-and-emergent-contaminants-and-risk-of-allergic-diseases-100556807","NCT06529913","Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases","Model of diseAses Related to Environmental Exposure to Heavy meTals, nanopaRticles and Emergent Contaminants, Using a dIgital platfOrm of Clinical and Bio-humoral Data: the Way to Susceptibility\u002FRisK BiomArker [MATRIOSKA Study] - The Seed.","MATRIOSKA","Inclusion Criteria:\n\n* adult subjects (over 18 years of age).\n* Subjects suffering from allergic contact dermatitis due to metals.\n* Subjects with systemic allergic syndrome due to metals.\n* Adult healthy subjects.\n* Subjects able to give written informed consent.\n\nExclusion Criteria:\n\n* Subjects under the age of 18years.\n* Pregnant\u002Fbreastfeeding women.\n* Subjects suffering from chronic renal failure requiring replacement treatment.\n* Subjects suffering from other systemic pathologies related to exposure to metals.\n* Subjects suffering from gastrointestinal diseases such as celiac disease, chronic inflammatory intestinal diseases, tumors, other skin diseases.\n* Subjects unable to express written informed consent.","18 Years",{"count":60,"type":22},280,"INTERVENTIONAL",[63],"NA","The goal of this clinical trial is to collect environmental, bio-humoral, and clinical data derived from patients with allergic contact dermatitis (ACD) and systemic metal allergic syndromes related to the exposure to heavy metals, nanoparticles, and emergent contaminants and from healthy subjects.\n\nThe main question it aims to answer is: are environmental, bio-humoral, and clinical data derived from patients with ACD and systemic metal allergic syndromes, related to the exposure to heavy metals, nanoparticles, and emergent contaminants, different from ones obtained by healthy subjects? Researchers will compare serum and urine concentration of heavy metals and nanoparticles, patch test to metals, within-breath analysis of oscillometry parameters, serum zonulin, and serum levels of protein oxidation products among patients with systemic allergic syndrome (1st study group), patients with ACD (2nd study group) and healthy subjects (3rd study group).\n\nParticipants will undergo:\n\n* measurement of exposure to heavy metals and nanoparticles including nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper, through serum and urine measurement of concentration.\n* Patch test to before mentioned metals.\n* Within-breath analysis of oscillometry parameters.\n* Measurement of serum zonulin (related to gastro-intestinal exposure).\n* Measurement of serum levels of protein oxidation products (as markers of systemic oxidative stress).",[66,67,68,69,70,71,72,73,74,27,26,75,76,77,78,79],"Allergic Contact Dermatitis","Metal Allergy","Food Allergy","Nickel Sensitivity","Nickel; Eczema","Aluminum Allergy","Chromium; Eczema","Functional Gastrointestinal Disorders","Respiratory Injury","Environmental Exposure","Environment Related Disease","Environmental Illness","Oxidative Stress","Risk Reduction",[67,81,82,83,84,85,86,87,88,89,66,68,73,74,75,90,91],"Nanoparticles","Emergent contaminants","Nickel","Aluminium","Copper","Chromium","Cobalt","Palladium","Titanium","Patch test","Biomarkers","2026-02-23",{"date":94,"type":41},"2026-02-24",{"date":96,"type":41},"2025-01-13",{"date":98,"type":22},"2026-12-31",{"name":100,"class":48},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":61,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":49},"100560038","phase-4-effect-of-the-inhaled-triple-therapies-over-the-small-airway-in-biomass-exposure-100560038","NCT06571942","Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","Effect of the Inhaled Triple Therapies Over the Small Airway in Patients With Chronic Obstructive Pulmonary Disease or Chronic Bronchitis Without Obstruction Secondary to Biomass Exposure: Randomized Controlled Clinical Trial Phase IV","Inclusion Criteria:\n\n* Subject capable of understanding instructions and giving her consent for participation.\n* Diagnosis of COPD or chronic bronchitis without obstruction due to biomass smoke exposure:\n\n  1. Diagnosis of COPD according to GOLD guidelines 2023 with: \\>100 hours-year of biomass exposure index, and with a post-bronchodilator spirometry FEV1 \\> 70% of predicted value.\n  2. Diagnosis of Chronic Bronchitis without obstruction with at least \\>100 hours-year of biomass smoke exposure index or more than 10 years of continued exposure to biomass smoke, and with 1) antecedent of chronic bronchitis, and 2) post-bronchodilator spirometry FEV1\u002FFVC \\>0.7.\n* Able to attend all visits.\n* Cooperative patients with adequate understanding and skill in using inhalers, or with caregivers capable of administering medications and filling out a daily symptom diary.\n* Stable patients, with no history of exacerbations in the last 4 weeks before inclusion.\n\nExclusion Criteria:\n\n* Pregnancy or in the breastfeeding period.\n* Documented allergy or intolerance to any of the study medications.\n* History of clinically significant bronchiectasis, tuberculosis, recent respiratory infection (4 weeks), or cardiovascular comorbidity that contraindicates pulmonary function tests or that influences their status and functional class.\n* Patients with suspicion or history of cancer.\n* Uncontrolled diseases: acute hyperthyroidism, acute uncontrolled DM2, acid-peptic disease that causes bleeding, uncontrolled hematological diseases, etc. In general, any decompensated disease that, in the opinion of the principal investigator, may influence the results of the study.","FEMALE","35 Years","85 Years",{"count":113,"type":22},128,[115],"PHASE4","This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months. As primary outcome, the resistance change in post-bronchodilatator impulse oscilometry will me measure at 30 minutes, 2 hours, 4 hours, and 24 hours post first dose of the asigned medication, and then at 1 and 3 months of treatment. As secondary outcomes, change in respiratory symptoms and health related quality of life will be assess after 1 and 3 months of treatment.",[118,26],"COPD Bronchitis",[120,121,122,123],"Biomass","COPD","Chronic bronchitis","Inhaled therapy","2024-08-25",{"date":126,"type":41},"2024-08-26",{"date":128,"type":41},"2023-11-15",{"date":130,"type":22},"2025-01-15",{"name":132,"class":133},"National Institute of Respiratory Diseases, Mexico","OTHER_GOV"]